VDR lack of evidence of risk of prostate cancer June 2009
Cancer Epidemiol Biomarkers Prev. 2009 Jun;18(6):1929-33. Epub 2009 May 19.
Vitamin D pathway gene variants and prostate cancer risk.
Holt SK, Kwon EM, Peters U, Ostrander EA, Stanford JL.
Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, Washington 98109, USA. skholt@fhcrc.org
Vitamin D has antiproliferative, antiangiogenic, and apoptotic properties. There is some evidence supporting an association between vitamin D-related gene variants and prostate cancer risk. We report results from this population-based case-control study of genes encoding for the vitamin D receptor (VDR), the vitamin D activating enzyme 1-alpha-hydroxylase (CYP27B1), and deactivating enzyme 24-hydroxylase (CYP24A1). Forty-eight tagging single nucleotide polymorphisms (tagSNP) were analyzed in 827 incident prostate cancer cases diagnosed from 2002 to 2005, and in 787 age-matched controls. 
Contrary to some earlier studies, we found no strong evidence of altered risk of developing prostate cancer overall or within clinical measures of tumor aggressiveness for any of the tagSNPs when they were assessed individually or in haplotypes.
PMID: 19454612 [PubMed - indexed for MEDLINE]
PMCID: PMC2743676 [Available on 2010/6/1]